Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023
Utilization of GLDs doubled, and associated costs tripled over the past 11 years, with no sign of either utilization or costs plateauing, predominantly due to increased GLP-1RA and SGLT2 inhibitor prescribing.
Authors
- Peter S. Hamblin (ORCID: https://orcid.org/0000-0002-6280-865X)
- Stella Talic (ORCID: https://orcid.org/0000-0001-7739-3381)
- Arul Earnest (ORCID: https://orcid.org/0000-0003-2693-5034)
- Sophia Zoungas (ORCID: https://orcid.org/0000-0003-2672-0949)
- Anthony Russell (ORCID: https://orcid.org/0000-0001-7886-8844)
- Ella Zomer (ORCID: https://orcid.org/0000-0002-9993-4297)
Institutions
- Western Health (AU)
- Alfred Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1111/dom.15893
- Citations
- 6
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.15